Acute kidney injury due to antimicrobial therapy
Authors:
Viktor Klementa 1; Naděžda Petejová 2; Josef Zadražil 1; Pavel Horák 1; Jitka Prošková 3; Olga Klementová 4
Authors‘ workplace:
III. interní klinika – nefrologická, revmatologická a endokrinologická LF UP a FN Olomouc
1; Interní a kardiologická klinika LF a FN Ostrava
2; oddělení klinické biochemie FN Olomouc
3; Klinika anesteziologie, resuscitace a intenzivní medicíny LF UP a FN Olomouc
4
Published in:
Vnitř Lék 2022; 68(4): 227-233
Category:
Review Articles
Overview
One of the common causes of acute kidney injury (AKI) is drug nephrotoxicity. A large group of drugs associated with AKI includes a considerable number of antimicrobials. Clinical manifestations range from mild forms of tubular damage to significant deterioration of renal function requiring renal replacement therapy. Several mechanisms have been described, although the most common are acute interstitial nephritis, acute tubular necrosis, crystalic nephropathy or proximal/distal tubulopathy with electrolyte abnormalities. General risk factors for antimicrobial-induced AKI include pre-existing chronic kidney disease and concomitant use of drugs with nephrotoxic potential. Prevention and early recognition of AKI are the standard approach to mitigate AKI and avoid morbidity.
Keywords:
Vancomycin – antibiotics – acute kidney injury – aminoglycosides
Sources
1. Ogobuiro I, Tuma F. Physiology, Renal. [Updated 2021 Jul 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi. nlm.nih.gov/books/NBK538339/
2. Pannu N, Nadim MK. An overview of drug‑ induced acute kidney injury. Crit Care Med 2008;36(4 Suppl.):S216–S223.
3. Chertow GM, Burdick E, Honour M et al. Acute kidney injury, mortality, lenght of stay, and cost in hospitalized patients. J Am Soc Nephrol. 2005; 16: 3365–3370.
4. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int. Suppl. 2012;2:1–138
5. Bentley ML, Corwin HL, Dasta J. Drug‑ induced acute kidney injury in the critically ill adult: Recognition and prevention strategies. Crit Care Med 2010; 38(6 Suppl.): S169–S174
6. Perazella MA, Markowitz GS. Drug‑ induced acute interstitial nephritis. Nat. Rev. Nephrol. 2010, 6, 461–470. [Google Scholar] [CrossRef] [PubMed]
7. Mulligan MJ, Cobbs CG. Bacteriostatic versus bactericidal activity. Infect Dis Clin North Am. 1989 Sep;3(3):389-98. PMID: 2671128.
8. Norrby SR. Neurotoxicity of carbapenem antibacterials. Drug Saf. 1996 Aug;15(2):87- 90. doi: 10.2165/00002018-199615020-00001. PMID: 8884160.
9. Krause KM, Serio AW, Kane TR et al. Aminoglycosides: An Overview. Cold Spring Harb Perspect Med. 2016 Jun 1;6(6):a027029. doi: 10.1101/cshperspect.a027029. PMID: 27252397; PMCID: PMC4888811.
10. Drew R. Aminoglycosides, doi: https://www.uptodate.com/contents/aminoglycosides? c si=caef2e4f-8240-441a-9b16-ad0d 8542df77 & source=contentShare
11. Humes HD. Aminoglycoside nephrotoxicity. Kidney Int 1988; 33:900.
12. McWilliam SJ, Antoine DJ, Smyth RL, et. al. Aminoglycoside‑ induced nephrotoxicity in children. Pediatr Nephrol. 2017;32:2015-25.
13. Denamur S, Boland L, Beyaert M et al. Subcellular mechanisms involved in apoptosis induced by aminoglycoside antibiotics: Insights on p53, proteasome and endoplasmic reticulum. Toxicol Appl Pharmacol. 2016;309:24-36.
14. Martinez‑Salgado C, Rodríguez‑Barbero A, Eleno N et al. Gentamicin induces Jun‑AP1 expression and JNK activation in renal glomeruli and cultured mesangial cells. Life Sci. 2005;77:2285-98.
15. Drew R, Sakoulas G. Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults, doi: https://www.uptodate.com/contents/vancomycin‑parenteral‑dosing‑monitoring‑and‑adverse‑effects‑in‑adults? csi=aaaf3a27-9cc2-461e-9987- b7c4170e7c41 & source=contentShare
16. Elyasi S, Khalili H, Dashti‑Khavidaki S et al. Vancomycin‑ induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol. 2012;68:1243-55.
17. Sinha Ray A, Haikal A, Hammoud KA, Yu AS. Vancomycin and the Risk of AKI: A Systematic Review and Meta‑Analysis. Clin J Am Soc Nephrol. 2016 Dec 7;11(12):2132-2140. doi: 10.2215/CJN.05920616. Epub 2016 Nov 28. PMID: 27895134; PMCID: PMC5142072.
18. Sawada A, Kawanishi K, Morikawa S et. al. Biopsy‑proven vancomycin‑ induced acute kidney injury: a case report and literature review. BMC Nephrol. 2018 Mar 27;19(1):72. doi: 10.1186/s12882-018-0845-1. PMID: 29587650; PMCID: PMC5872390.
19. Petejova N, Martinek A, Zahalkova J et. al. Vancomycin removal during low‑flux and high‑flux extended daily hemodialysis in critically ill septic patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012 Dec;156(4):342-7. doi: 10.5507/bp.2012.002. Epub 2012 Jan 30. PMID: 22660225.
20. Cai Y, Lee W, Kwa AL. Polymyxin B versus colistin: an update. Expert Rev Anti Infect Ther. 2015;13(12):1481-97. doi: 10.1586/14787210.2015.1093933. Epub 2015 Oct 21. PMID: 26488563.
21. MacLaren G, Spelman D. Polymyxins: An overview, doi: https://www.uptodate.com/ contents/polymyxins‑an‑overview? csi=119451e1-13c2-436d-810c-7ec1fdfad5f1 & source= contentShare
22. Lima LM, Silva BNMD, Barbosa G et al. β‑ lactam antibiotics: An overview from a medicinal chemistry perspective. Eur J Med Chem. 2020 Dec 15;208:112829. doi: 10.1016/j. ejmech.2020.112829. Epub 2020 Sep 16. PMID: 33002736.
23. González E, Gutiérrez E, Galeano C et al. Early steroid treatment improves the recovery of renal function in patients with drug‑ induced acute interstitial nephritis. Kidney Int. 2008;73:940-6.
24. Burgess LD, Drew RH. Comparison of the incidence of vancomycin‑ induced nephrotoxicity in hospitalized patients with and without concomitant piperacillintazobactam. Pharmacotherapy. 2014;34:670-6.
25. Gomes DM, Smotherman C, Birch A et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin‑tazobactam or cefepime. Pharmacotherapy. 2014;34:662-9.
26. Navalkele B, Pogue JM, Karino S et al. Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin‑Tazobactam Compared to Those on Vancomycin and Cefepime. Clin Infect, DiS. 2017;64:116- 23.
27. Mansoor GA, Panner BJ, Ornt DB. Azithromycin‑induced acute interstitial nephritis. Ann Intern Med 1993;119:636-7.
28. Persico C, Rocchi A, Edefonti A et. al. The acute interstitial nephritis induced by azithromycin. NDT Plus. 2011;4:218.
29. Woodruff AE, Meaney CJ, Hansen EA et. al. Azithromycin‑Induced, Biopsy‑Proven Acute Interstitial Nephritis in an Adult Successfully Treated with Low‑Dose Corticosteroids. Pharmacotherapy. 2015;35:e169-74.
30. Russell W, Smith W. Clarithromycin‑induced acute interstitial nephritis and minimal change disease. NDT Plus. 2009;2:382-3.
31. Gandhi S, Fleet JL, Bailey DG et. al. Calcium‑channel blocker‑clarithromycin drug interactions and acute kidney injury. JAMA. 2013;310:2544-53.
32. Mishima E, Maruyama K, Nakazawa T et. al. Acute Kidney Injury from Excessive Potentiation of Calcium‑channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole. Intern Med. 2017;56:1687-90
33. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. doi: 10.1128/mmbr.61. 3. 377-392.1997. PMID: 9293187; PMCID: PMC232616.
34. Bolon B. Mini‑Review: Toxic Tendinopathy. Toxicol Pathol. 2017 Oct;45(7):834-837. doi: 10.1177/0192623317711614. Epub 2017 May 28. PMID: 28553748.
35. Bird ST, Etminan M, Brophy JM, et. al. Risk of acute kidney injury associated with the use of fluoroquinolones. CMAJ. 2013;185:E475-82.
36. Muriithi AK, Leung N, Valeri AM et al. Biopsy‑proven acute interstitial nephritis, 1993- 2011: a case series. Am J Kidney, DiS. 2014;64:558-66.
37. Khan M, Ortega LM, Bagwan N et. al. Crystal‑ induced acute kidney injury due to ciprofloxacin. J Nephropathol. 2015;4:29-31.
38. Li Y, Zhu Y, Zhong Q et al. Serious Adverse Reactions From Anti‑tuberculosis Drugs Among 599 Children Hospitalized for Tuberculosis. Pediatr Infect Dis J. 2017;36:720-5.
39. Wortham JM, Goggin M, Mora C et. al. Acute kidney injury during treatment for latent tuberculous infection with rifampin. Int J Tuberc Lung, DiS. 2017;21:596-7.
40. Chang CH, Chen YF, Wu VC et al. Acute kidney injury due to anti‑tuberculosis drugs: a five‑year experience in an aging population. BMC Infect, DiS. 2014;14:23.
41. Drew R, Sterling T. Antituberculous drugs: An overview, doi: https://www.uptodate. com/contents/antituberculous‑drugs‑an‑overview? search=antimyco bacterials & source=- search_result & selectedTitle=1~150 & usage_type=default & display_rank=1
42. Rhodes A, Evans LE, Alhazzani W et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017 Mar;43(3):304-377. doi: 10.1007/s00134-017-4683-6. Epub 2017 Jan 18. PMID: 28101605.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2022 Issue 4
Most read in this issue
- Development of recommendations for the use of venoactive drugs in the treatment of chronic venous disease – where they are effective and where they are not
- Acetylsalicylic acid in primary prevention of cardiovascular disease
- COVID-19 and post-COVID – Jekyll and Hyde of modern medicine
- Acute kidney injury due to antimicrobial therapy